6 APPENDICES
6.3 APPENDIX 3: FINAL SET OF INDICATOR FOR RECTAL, BREAST AND TESTICULAR
Table 16. Final sets of quality indicators for rectal, breast and testicular cancer.
Rectal cancer Breast cancer Testicular cancer General Quality indicators: outcomes
Overall 5-year survival by stage Overall 5-year survival by stage Overall 5-year survival by stage Disease-specific 5-year survival by stage Disease-specific 5-year survival by stage Disease-specific 5-year survival by stage Proportion of patients with local recurrence Disease-free 5-year survival by stage Disease-free 5-year survival by stage 5-year local recurrence after curative surgery, by stage
General Quality indicators: processes
Proportion of patients discussed at a MDT meeting Proportion of breast cancer women discussed at the MDT
meeting Proportion of patients with testicular cancer
discussed at the MDT meeting Proportion of women with breast cancer who participate in
clinical trials
Proportion of patients with relapsing testicular cancer after curative treatment that are included in a clinical trial
Diagnosis and staging
Proportion of patients with a documented distance from the anal verge
Proportion of women with class 3, 4 or 5 abnormal mammograms having an assessment with a specialist within 2 months of mammography
Proportion of patients with testicular cancer undergoing tumour marker assessment before any treatment
Proportion of patients in whom a CT of the liver and RX or CT of the thorax was performed before any treatment
Proportion of women with class 3, 4 or 5 abnormal mammograms who have at least one of the following procedures within 2 months after communication of the screening result: mammography, ultrasound, fine-needle aspiration, or percutaneous biopsy
Proportion of patients with testicular cancer undergoing contrast-enhanced Computed Tomography (CE-CT) or Magnetic Resonance Imaging (MRI) for primary staging
Proportion of patients in whom a CEA was performed
before any treatment Proportion of newly diagnosed cstage I-III breast cancer women who underwent two-view mammography or breast sonography within 3 months prior to surgery
Proportion of patients undergoing elective surgery that had
preoperative complete large bowel-imaging Proportion of women who received axillary
ultrasonography with fine needle aspiration cytology of the axillary lymph nodes before any treatment
Proportion of patients in whom a TRUS and pelvic CT
and/or pelvic MRI was performed before any treatment Proportion of women in whom human epidermal growth factor receptor 2 status was assessed before any systemic treatment
Proportion of patients with cStage II-III that have a reported Proportion of women in whom a ER and PgR status
Rectal cancer Breast cancer Testicular cancer
cCRM assessment were performed before any systemic treatment
Time between first histopathologic diagnosis and first treatment
Proportion of breast cancer women with cytological and/or histological assessment before surgery
Neoadjuvant treatment
Proportion of cStage II-III patients that received a short
course of neoadjuvant pelvic RT Proportion of operable cT2-T3 women who received neoadjuvant systemic therapy
Proportion of cStage II-III patients that received a long course of neoadjuvant pelvic RT
Proportion of cStage II-III patients that received neoadjuvant chemoradiation with a regimen containing 5-FU
Proportion of cStage II-III patients treated with neoadjuvant 5-FU based chemoradiation, that received a continuous infusion of 5-FU
Proportion of cStage II-III patients treated with a long course of preoperative pelvic RT or chemoradiation, that completed this neoadjuvant treatment within the planned timing
Proportion of cStage II-III patients treated with a long course of preoperative pelvic RT or chemoradiation, that was operated 6 to 8 weeks after completion of the (chemo)radiation
Rate of acute grade 4 radio(chemo)therapy-related complications
Surgery
Proportion of R0 resections Proportion of breast cancer women who underwent an axillary lymph node dissection (ALND) after positive SNLB
> 2 mm
Number of annually surgically treated patients with testicular cancer per centre
Proportion of APR and Hartmann’s procedures Proportion of women with high-grade and/or palpable and/or large DCIS of the breast who had negative margins after surgery, whatever the surgical option (local wide excision or mastectomy)
Proportion of patients with stoma 1 year after sphincter-sparing surgery
Proportion of cStage I and II women who undergo breast-conserving surgery (BCS) / mastectomy
Rectal cancer Breast cancer Testicular cancer Rate of patients with major leakage of the anastomosis after
sphincter-sparing surgery
Proportion of women with breast cancer recurrence after breast conserving surgery who are treated by a mastectomy Inpatient or 30-day mortality
Rate of intra-operative rectal perforation (Adjuvant) treatment
Proportion of p-ypStage III patients with R0 resection that
received adjuvant chemotherapy Proportion of women with a breast cancer who are receiving intravenous chemotherapy for whom the planned chemotherapy regimen (which includes, at a minimum:
drug[s] prescribed, dose, and duration) is documented prior to the initiation, and at each administration of the treatment regimen
Radiation dose and field in patients with testicular cancer treated with radiotherapy by stage
Proportion of pStage II-III patients with R0 resection that received adjuvant radiotherapy or chemoradiotherapy
Proportion of women receiving adjuvant systemic therapy after breast surgery for invasive breast cancer
Proportion of patients with stage I non-seminoma treated with active surveillance Proportion of p-ypStage II-III patients with R0 resection that
started adjuvant chemotherapy within 3 months after surgical resection
Proportion of women with hormone receptor positive invasive breast cancer or ductal carcinoma in situ (DCIS) who received adjuvant endocrine treatment (Tamoxifen/AI)
Proportion of patients receiving CE-CT or MRI for residual disease assessment at the end of systemic treatment
Proportion of p-ypStage II-III patients with R0 resection treated with adjuvant chemo(radio)therapy, that received 5-FU based chemotherapy
Proportion of women with HER2 positive, node positive or high-risk node negative breast cancer (tumour size > 1 cm), having a left ventricular ejection fraction of ≥50-55% who received chemotherapy and Trastuzumab
Degree and duration of active surveillance in patients with stage I non-seminoma or seminoma
Rate of acute grade 4 radio- or chemotherapy-related
complications Proportion of women treated by Trastuzumab in whom
cardiac function is monitored every 3 months
Proportion of women who received radiotherapy after breast conserving surgery
Proportion of women who underwent a mastectomy and having ≥ 4 positive nodes who received radiotherapy on axilla following ALND
Proportion of women with HER2 positive metastatic breast cancer who received Trastuzumab with/without non-anthracycline based chemotherapy or endocrine therapy as first-line treatment
Proportion of metastatic breast cancer women who receive systemic therapy as 1st and/or 2nd line treatment
Proportion of women with metastatic breast cancer and
Rectal cancer Breast cancer Testicular cancer lytic bone metastases who received biphosphonates
Palliative care
Rate of cStage IV patients receiving chemotherapy
Rate of acute grade 4 chemotherapy-related complications in stage IV patients
Follow-up
Rate of curatively treated patients that received a total colonoscopy within 1 year after resection
Proportion of women who benefit from an annual mammography after a history of breast cancer Rate of patients undergoing regular follow-up (according to
the PROCARE recommendations)
Late grade 4 complications of radiotherapy or chemoradiation
Histopathologic examination
Use of the pathology report sheet Proportion of breast cancer resection pathology reports that include the tumour size (macro-and microscopically invasive and DCIS), the histologic type of the primary tumour, the pT category (primary tumour), the pN category (regional lymph nodes including numbers), the lymphovascular invasion (LVI) and the histologic grade.
Quality of TME assessed according to Quirke and
mentioned in the pathology report Proportion of women with invasive breast cancer undergoing ALND and having 10 or more lymph nodes removed
Distal tumour-free margin mentioned in the pathology report
Number of lymph nodes examined
(y)pCRM mentioned in mm in the pathology report Tumour regression grade mentioned in the pathology report (after neoadjuvant treatment)